UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000013453
Receipt No. R000015709
Scientific Title A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody
Date of disclosure of the study information 2014/03/18
Last modified on 2020/08/20 23:57:46

No. Disposal Last modified on Item of update
1 Insert 2014/03/18 16:00:14
2 Update 2014/08/17 21:41:48 Recruitment status
3 Update 2014/10/20 15:43:35 Key exclusion criteria
Key exclusion criteria
4 Update 2015/04/17 14:35:06 Anticipated trial start date
5 Update 2015/04/17 14:49:31 Organization
Organization
Research ethics review
Institutions
6 Update 2015/04/17 14:58:44 Homepage URL
7 Update 2016/03/18 10:02:10 Organization
Institutions
8 Update 2016/10/21 09:30:59 Name of primary sponsor
Institute
Organization
Organization
Category of Funding Organization
9 Update 2017/11/10 15:19:17 Recruitment status
Last follow-up date
10 Update 2018/12/19 12:20:13 Email
Email
Email
11 Update 2019/03/28 13:30:06 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Organization
Zip code

Last name of contact person

Last name of contact person
Organization
Zip code
Organization
Organization
Institute
Organization
Organization
Address
Address
Tel
Email
12 Update 2019/03/28 13:35:54 Date of IRB
13 Update 2019/03/28 13:37:30 Number of participants that the trial has enrolled
14 Update 2019/09/13 10:33:44 Recruitment status
Date of closure to data entry
Date trial data considered complete
15 Update 2020/08/20 23:57:46 URL releasing protocol
Publication of results
URL related to results and publications
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures


Contact us.